Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Yoga for the Management of HIV-Metabolic Syndromes

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00627380
First received: February 28, 2008
Last updated: July 23, 2010
Last verified: July 2010

February 28, 2008
July 23, 2010
November 2005
June 2009   (final data collection date for primary outcome measure)
The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00627380 on ClinicalTrials.gov Archive Site
  • Fasting lipid/lipoprotein levels. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Body composition: visceral and subcutaneous adipose tissue areas (VAT, SAT), trunk/limb adipose ratio. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Cardiovascular disease risk: Framingham 10-yr CVD risk calculation [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Quality of life: SF36 MOS [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Safety: CD4 count and plasma HIV RNA [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Yoga for the Management of HIV-Metabolic Syndromes
Yoga for the Management of HIV-Metabolic Syndromes

We are testing the safety and efficacy of a 16-wk yoga lifestyle intervention on oral glucose tolerance, fasting lipid/lipoprotein levels, body composition, cardiovascular function, quality of life, CD4+ T-cell counts and viral load in HIV-infected men and women with components of The Metabolic Syndrome. We hypothesize that a yoga lifestyle intervention will improve metabolic, anthropometric, cardiovascular disease parameters, and quality of life domains without adversely affecting immune or virologic status in people living with HIV.

Very few safe, effective, and novel treatments for metabolic syndromes that develop in HIV-infected people exist. These metabolic syndromes may increase cardiovascular disease risk in HIV-infected people and may reduce their quantity and quality of life. Practicing a yoga lifestyle intervention may provide a safe, effective and novel therapy for HIV metabolic syndromes, but this alternative form of therapy has not been tested in HIV-infected people with metabolic syndromes. In men and women with HIV-related metabolic syndromes, we will determine:

  1. The safety of practicing a yoga lifestyle in HIV-infected people treated with HAART who are experiencing metabolic and anthropometric syndromes.
  2. To quantify the effects of practicing a yoga lifestyle on metabolic and anthropomorphic syndromes in HIV-infected people treated with HAART who are experiencing these syndromes.
  3. To quantify the effects of practicing a yoga lifestyle on cardiovascular disease (CVD) risk in HIV-infected people treated with HAART who are at increased CVD risk because of existing metabolic and anthropomorphic syndromes.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV Infections
  • HIV Metabolic Cardiovascular Syndrome
  • HIV Lipodystrophy
  • HIV Metabolic Syndromes
  • Hypertension
  • Behavioral: Yoga lifestyle intervention
    Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
    Other Names:
    • Hatha yoga
    • Ashtanga yoga
  • Other: Standard of care
    Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
    Other Name: Observation control group
  • Placebo Comparator: STOC
    Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
    Intervention: Other: Standard of care
  • Experimental: YOGA
    Yoga lifestyle intervention administered by certified yoga instructor.
    Intervention: Behavioral: Yoga lifestyle intervention

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-infected volunteers must have dyslipidemia (fasting serum LDL-cholesterol >100mg/dL, or
  • triglycerides >200mg/dL, or
  • HDL-cholesterol <40mg/dL (men) or <50mg/dL (women), or
  • impaired glucose tolerance (fasting blood glucose 100-140mg/dL or
  • fasting insulin 13-45µU/mL or 2hr glucose during the oGTT 140-200mg/dL),or
  • central adiposity (waist circumference >102 cm (40inches in men) or >88cm (35inches in women)
  • The purpose is to identify and enroll participants with a clear proatherogenic lipid profile
  • increased CVD risk
  • abdominal adiposity, and fasting glucose intolerance or insulin resistance
  • but not type 2 diabetics who have normalized their blood sugars using glucose-lowering agents. If a type 2 diabetic uses a glucose-lowering medication, but they are still insulin resistant/glucose intolerant (by above criteria), they are eligible to participate, because we are testing the added benefits of yoga therapy on a defined dysmetabolic syndrome in participants who are stable on the standard-of-care for these metabolic syndromes, and this includes glucose- and lipid-lowering agents
  • These criteria must be met, even in volunteers receiving glucose- or lipid-lowering agents, so that we enroll participants who have developed metabolic syndromes that are not normalized by traditional pharmacologic approaches
  • Volunteers receiving glucose- or lipid-lowering agents who have normalized their lipid, glucose and insulin levels below these defined limits, are not eligible to enroll.

Additional Inclusion Criteria.

  • 18-70 years old.
  • Plasma HIV RNA <15,000 copies/ml for previous 3months.
  • CD4 count >200 c/µL for previous 3 months.
  • Stable HIV RNA level and stable CD4 count for at least the past 3 months. Some HIV-infected people can accomplish this while not receiving HAART (eg. long term non-progressors) and will be included. But, most of the participants will be on a HAART regimen that includes either 2 NRTIs + NNRTI, or 2NRTIs + PI, or NRTI+NNRTI+PI
  • "Normal" blood chemistries for at least 1 month prior to enrollment:

    • platelet count >30,000/mm3
    • absolute neutrophil count >750/mm3
    • transaminases <5x the upper limit of normal
    • creatinine <3x the upper limit of normal
    • albumin >30g/L

Exclusion Criteria:

  • Chronic hepatitis B infection (HB surface antigen positive). Active hepatitis C infection (detectable Hep C RNA). Those who have cleared hepatitis B or C infection are eligible.
  • Diabetes [fasting glucose >140 mg/dL, or fasting insulin >45 µU/mL, or 2-hr glucose >200mg/dL].
  • History of diabetes mellitus that pre-dates HIV-infection. Medications or agents that regulate glucose or lipid metabolism (e.g., insulin-sensitizers, insulin-secretagogues, HMG-CoA reductase inhibitors ('statins'), fibrates, niacin) are permitted. A large percentage of ACTU subjects and ID Clinic patients receiving RTV-boosted regimens are also receiving lipid-lowering agents. Excluding them might significantly reduce the pool of potential enrollees. The glucose- or lipid-lowering agent and dose must be stable for at least 3 months prior to screening. Additionally, volunteers taking glucose-or lipid-lowering agents must still have dyslipidemia and impaired glucose tolerance criteria (above). If they are taking these agents and have 'normalized' their lipids/lipoproteins and hyperinsulinemia, then they are not eligible
  • Gestational diabetes, pregnancy, or nursing mothers. Menstruating women must have a negative urine pregnancy test within 14 days prior to DEXA testing (minor radiation exposure from DEXA). To control for potential metabolic effects of alterations in female hormones during the menstrual cycle, all menstruating women will be tested during the follicular phase.
  • Hypogonadism [total testosterone <200ng/dL (men) or <15ng/dL (women)]; thyroid disorder [TSH <0.2 or >12µIU/mL]; hypercortisolemia [morning cortisol >22µg/dL]. Replacement testosterone or thyroid hormones or human growth hormone to normalize abnormal levels is acceptable, as long as treatment has been stable, and blood testosterone, TSH or IGF-1 levels are within the normal range.
  • Unwilling or unable to attend supervised yoga sessions 3days/wk provided by Brentwood Center for Health at the Connectcare Clinic. Any condition that might be contraindicated for yoga therapy (disabling neuromuscular or musculoskeletal injury/disorder)
  • History of serious cardiovascular disease; MI, unstable angina, heart failure, congenital heart disease, coronary artery disease, resting ST-segment depression >1mm, coronary artery bypass graft, stroke, sinus tachycardia, arrhythmias, premature atrial or ventricular contractions, claudication. Bundle branch block is exclusionary because it limits the interpretability of the resting/exercise ECG. Cardiovascular contraindications to maximal exercise testing
  • Anticipated change in anti-HIV medications or other medications that affect metabolism, within the next 4months
  • Well-trained athletes (defined as >3 exercise training exposures/week; >30min regimented exercise/exposure maintained for at least the prior 4 weeks)
  • Active substance abuse (eg, alcoholism, cocaine, heroin, crack, methamphetamine, phencyclidine)
  • Active secondary infection or a significant change in chronic suppressive therapy for an opportunistic infection during 1 month prior to enrollment
  • New serious systemic infection during the 3 weeks prior to enrollment
  • Recent episode of hyperlactatemia or lactic acidosis, esp. with rapid weight loss
  • Chronic renal insufficiency/failure or other comorbid conditions (eg. cancer, COPD) that alter metabolism
  • Pancreatitis, celiac disease, or cirrhosis
  • Inadequate macronutrient or energy intake, or malabsorptive disorder as determined by the research dietician
  • Dementia or any condition that would prevent voluntary informed consent or compliance
  • Other compounds or blinded investigational new drugs that might affect metabolism or confound data interpretation (eg. RU486, interleukin therapy, or cytokine-receptor antagonist)
  • Oral glucocorticoid or corticosteroid use within the previous 3 months
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00627380
R21 AT003083, R21AT003083, WU187
Yes
Kevin E. Yarasheski/Principal Investigator, Washington University
Washington University School of Medicine
National Center for Complementary and Alternative Medicine (NCCAM)
Principal Investigator: Kevin E Yarasheski, PhD Washington University School of Medicine
Washington University School of Medicine
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP